Protective effects of renin - Angiotensin blockade beyond blood pressure control

Journal of Human Hypertension

Volumn 23, Issue 9, 2009, Pages 570-577

  Mancia, G ^a,b   Giannattasio, C ^a,b   Seravalle, G ^b   Quarti Trevano, F ^a   Grassi, G ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ATENOLOL; C REACTIVE PROTEIN; CANDESARTAN; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LACIDIPINE; LOSARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRAIN CIRCULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG TOLERABILITY; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HOSPITALIZATION; HUMAN; HYPERTENSION; MICROCIRCULATION; OUTCOME ASSESSMENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 69549084749     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.171     Document Type: Review

References (52)

1. Mancia G, Parati G. Guiding antihypertensive treatment decisions using ambulatory blood pressure monitoring. Curr Hypertens Rep 2006; 8: 330-337.
2. Zanchetti A, Bond G, Hennig M, Neiss A, Mancia G, Dal Palù C et al. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-2427.
3. Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: Data from the European Lacidipine Study on Atherosclerosis. J Hypertens 2007; 25: 1087-1094.
4. Mancia G, Omboni S, Parati G, Clement DL, Haley WE, Rahman SN et al. Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. J Hypertens 2001; 19: 1755-1763.
5. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436.
6. Zanchetti A, Crepaldi G, Bond MG, Gallus G, Veglia F, Mancia G et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: Principal results of PHYLLIS - a randomized double-blind trial. Stroke 2004; 35 2807-2812.
7. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: An update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28: 385-407.
8. Williams B. Recent hypertension trials: Implications and controversies. J Am Coll Cardiol 2005; 45: 813-827.
9. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population. Circulation 2005; 111: 1777-1783.
10. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47: 846-853.
11. Mancia G. Effective ambulatory blood pressure control in medical practice. Good news to be taken with caution. Hypertension 2007; 49: 17-18.
12. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation 2003; 107: 1401-1406.
13. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-h blood pressure variability. J Hypertens 1993; 11: 1133-1137.
14. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118-123.
15. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 1213-1225.
16. Grassi G. Intermediate versus hard end points in clinical trials on hypertension. Curr Hypertens Rep 2005; 7: 294-297.
17. Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, et al., ALLHAT Collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: Diagnosis and prognosis. Am Heart J 2007; 153: 42-53.
18. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003.
19. Bang LE, Wiinberg N, Wachtell K, Larsen J, Olsen MH, Tuxen C et al. Losartan versus atenolol on 24-h ambulatory blood pressure. A LIFE substudy. Blood Press 2007; 16: 392-397.
20. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al., MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226.
21. Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, et al., Jikei Heart Study group. Valsartan in a Japanese population with a hypertension and other cardiovascular disease (Jikei Heart Study): A randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439.
22. López-Farré A, Sánchez de Miguel L, Montón M, Jiménez A, Lopez-Bloya A, Gómez J et al. Angiotensin II AT(1) receptor antagonists and platelet activation. Nephrol Dial Transplant 2001; 16(Suppl 1): 45-49.
23. Petnehazy T, Stokes KY, Russell JM, Granger DN. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules. Hypertension 2005; 45: 209-215.
24. Siragy HM. Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Curr Hypertens Rep 2008; 10: 261-267.
25. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the ARB-MI paradox. Circulation 2006; 114: 838-854.
26. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111 2518-2524.
27. Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: Role of bradykinin and nitric oxide. J Hypertens (Suppl) 2006; 24: S39-S43.
28. Mancia G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Grassi G. Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens (Suppl) 2006; 24: S51-S56.
29. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10.
30. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
31. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693-704.
32. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: Deeds and misdeeds. J Hypertens 2005; 23 2113-2118.
33. Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006; 114: 855-860.
34. Blood Pressure Lowering Treatment Trialists' Collaboration-Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-958.
35. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
36. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419.
37. Schrader J, Kulschewski A, Dendorfer A. Inhibition of the renin-angiotensin system and the prevention of stroke. Am J Cardiovasc Drugs 2007; 7: 25-37.
38. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
39. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomized controlled trial. Lancet 2008; 372: 1174-1183.
40. Schneider MP, Klingbeil AU, Delles C, Ludwig M, Kolloch RE, Krekler M et al. Effect of irbesartan versus atenolol on left ventricular mass and voltage: Results of the CardioVascular Irbesartan Project. Hypertension 2004; 44: 61-66.
41. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855-1864.
42. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: The candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-2300.
43. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 2116-2123.
44. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110: 1456-1462.
45. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review. J Hypertens 2006; 24: 983-991.
46. Mulvany MJ. Resistance vessel growth and remodelling: Cause or consequence in cardiovascular disease. J Hum Hypertens 1995; 9 479-485.
47. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
48. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002; 20: 71-78.
49. Rizzoni D, Porteri E, De Ciuceis C, Sleiman I, Rodella L, Rezzani R et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension 2005; 45 659-665.
50. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225-1237.
51. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419.
52. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: A meta-analysis. J Hypertens 2008; 26: 1282-1289.